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Abstract 12 
Extracellular surface proteins can be used to identify fully functional human mesenchymal 13 
stem cells (hMSCs) in a mixed population. Here a multiparameter flow cytometry assay was 14 
developed in order to examine the expression of several bone marrow-derived hMSC markers 15 
simultaneously at the single cell level. The multiparameter approach demonstrates a depth of 16 
analysis that goes far beyond the conventional single or dual staining methods. CD73, CD90 17 
and CD105 were chosen as positive markers as they are expressed on multipotent hMSCs, 18 
whilst CD34 and HLA-DR were chosen as negative indicators. Single colour analysis 19 
suggested a population purity of 100%, in contrast, when analysed via the multiparameter 20 
method it was found that the CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/CD34-ve phenotype 21 
represented 94.49% ± 1.31% of the total cell population. Also, CD271 has recently been 22 
posited as a definite early stage hMSC marker but here we show it is not present on pre-23 
passage cells, highlighting the need for careful marker selection.  24 
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Introduction 29 
Human mesenchymal stem cells (hMSCs), also known as multipotent stromal cells, were first 30 
isolated from bone marrow and found to differentiate into adipocytes, chondrocytes and 31 
osteoblasts in vitro (Pittenger et al. 1999; Friedenstein et al. 1970). In addition, it is now 32 
known that hMSCs secrete multiple anti-inflammatory, angiogenic and immunomodulatory 33 
factors that serve to repair locally damaged tissue (Caplan 2007). For these reasons they are 34 
becoming a cell type of increasing interest for tissue engineering and regenerative medicine 35 
research. Currently there are over 150 active bone marrow-derived mesenchymal stem cell 36 
clinical trials with only a handful in phase 3; hence there is now a real need for robust product 37 
characterisation (http://www.clinicaltrials.gov/).  38 
 39 
Mesenchymal stem cells are not unique to bone marrow; they have also been isolated from 40 
dental pulp, umbilical cord vein and adipose tissue (Williams and Hare 2011). The varied 41 
tissue sources and isolation techniques used raise the issue of whether the resulting cell 42 
populations are true hMSCs at all and whether the many published studies conducted are at 43 
all comparable (for a comprehensive review see (Rojewski et al. 2008)). Currently there is no 44 
single marker that defines an hMSC and therefore investigators will use a combination of 45 
markers to characterise a population. To address this concern the International Society for 46 
Cellular Therapies (ISCT) has proposed minimal criteria that define a true hMSC (Dominici 47 
et al. 2006). These include the ability to adhere to standard tissue culture plastic; 48 
differentiation into the adipocytes, chondrocytes and osteoblasts lineages; and expression of 49 
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specific surface antigen markers. These surface antigens include expression of CD90, CD73 50 
and CD105; hMSCs must also lack the expression of CD45, CD34, CD14, CD79α and HLA-51 
DR as they are indicators of non-stromal cell types. Recently this has been updated to include 52 
CD10, CD146 and GD2 as further positive markers (Rasini et al. 2013). 53 
 54 
Recently, it has been suggested that another marker, CD271 (Low-Affinity Nerve Growth 55 
Factor Receptor), may in fact be specific for the colony-forming-unit-fibroblast (CFU-Fs) 56 
found in the stromal region (Jones et al. 2006; Kuci et al. 2010). Previous studies have 57 
demonstrated via fluorescent-activated cell sorting (FACS) that by collecting CD271+ve cells, 58 
the resulting population has a greater CFU-F capability when compared to a population of 59 
non-sorted cells. However, it is known to be down-regulated over prolonged culture in vitro 60 
suggesting it may be an efficient marker to initially select for bone marrow hMSCs but not as 61 
a positive phenotypic marker over multiple passages (Harichandan and Buhring 2011). 62 
 63 
Flow cytometry is a high-throughput analytical technique that can be used to study protein 64 
expression properties of a cell via fluorescently labelled monoclonal antibodies. Most flow 65 
cytometers can measure the expression of several antigens provided that a sample is split for 66 
analysis using one or two fluorophore-labelled antibodies at a time. While technically 67 
straightforward, single or dual staining approaches do not provide the resolution of multiple 68 
antigens within the same population. Multiparameter (also known as multicolour) flow 69 
cytometry has been applied to clinical diagnostics and immunology, providing the high-70 
resolution information needed to identify subtle phenotypic differences with statistical 71 
robustness (Peters and Ansari 2011). Unfortunately, multiparameter flow cytometry is not 72 
routinely used to define stem cell phenotypes, although a previous study has demonstrated the 73 
use of a seven-colour flow cytometry assay to examine the differential expression of markers 74 
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between freshly isolated bone marrow and umbilical cord samples (Martins et al. 2009). 75 
However, it is envisaged that greater uptake of multiparameter flow cytometry is expected to 76 
provide similar benefits to those achieved in the aforementioned fields of research. 77 
 78 
Previous work by our laboratory has demonstrated that multiparameter flow cytometry can be 79 
used to characterise human embryonic stem cells (Brosnan et al. 2013). Here we show that 80 
this technique can be used to monitor five surface antigens that correspond to the hMSC 81 
phenotype. CD73, CD90 and CD105 were selected, as they are the most widely accepted 82 
surface markers of multipotency, additionally we also examine CD271 as a potential positive 83 
marker. CD34 and HLA-DR were selected as negative markers, as they indicate 84 
differentiation down the primitive hematopoietic and leukocyte lineages respectively.  85 
 86 
Here we demonstrate the power of a relatively simple and cost effective assay using a five-87 
colour/two laser array for the analysis of extracellular marker expression on hMSCs. The 88 
multiparameter approach provides a simple way to determine putative hMSCs from a mixed 89 
population and for quality control that can be implemented to further facilitate process 90 
development. 91 
 92 
Materials & Methods 93 
Cell Culture 94 
 95 
Human bone marrow derived mesenchymal stem cells (Lonza, Germany) were obtained from 96 
a single healthy donor after the patient provided informed consent. The local Ethical 97 
Committee approved the use of the sample for research. hMSCs passage 2-6 were cultured in 98 
DMEM supplemented with 10% (v/v) foetal bovine serum (FBS; Hyclone, Belgium) and 2 99 
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mM L-glutamine (Lonza, UK); medium was replaced every 3 days. Cells were maintained in 100 
a humidified incubator at 37°C in air containing 5% v/v CO2. The cells were passaged every 101 
6 days using 3ml 0.25% w/w trypsin/EDTA (Lonza, UK) for 5 minutes at 37°C then 102 
quenched with 7ml growth medium. The cells were detached by gentle tapping and the cell 103 
suspension was centrifuged for 5 minutes at 220g. The supernatant was discarded and the 104 
remaining pellet was re-suspended in an appropriate volume of culture medium. The hMSCs 105 
were reseeded at 5x103 cells/cm2 in T-flasks. 106 
Cell Separation 107 
 108 
Bone marrow mononuclear cells (BM-MNC) samples, obtained from donors 080004A and 109 
071475B with informed consent, were purchased from Lonza (US). Both samples were sorted 110 
using manual magnetic-activated cell sorting (MACS) (Miltenyi Biotech, UK) according to 111 
the manufacturer’s instructions. Briefly, the BM-MNC were incubated with CD271-PE 112 
antibody and blocking agent for 10 minutes at 4°C. Then the samples were washed in buffer, 113 
centrifuged and the supernatant aspirated. The samples were then conjugated with anti-PE 114 
microbeads for 15 minutes at 4°C. A LS MACS column was used to isolate both the 115 
CD271+ve and CD271-ve   cell fractions which were both plated into separate T-flasks.   116 
Antibody Staining 117 
 118 
Detached cells were suspended at 0.5x106 cells/ml in growth medium and loaded onto a 96 119 
well plate (200µl per well). The plate was centrifuged for 5 minutes at 220g. The aspirate was 120 
removed and the cells re-suspended and washed in flow cytometry staining buffer (R&D 121 
Systems, UK) and the centrifugation cycle repeated. The cells were stained for 30 minutes in 122 
the dark at room temperature with fluorescent monoclonal antibodies against CD34 (PE-123 
CY5), CD73 (PE-Cy7), CD90 (APC), CD105 (PE) and HLA-DR (FITC, all from BD 124 
Biosciences, UK) in addition with the corresponding isotype controls. After incubation the 125 
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cells were washed twice with staining buffer as before. Finally, 200µl of staining buffer was 126 
used to re-suspend the samples before analysis.  For CD45/CD271 staining BM-MNC were 127 
thawed and dual stained with both CD45 (APC-Cy7, BD Biosciences, UK) and CD271 (PE, 128 
Miltenyi Biotec, UK) antibodies using the same protocol as before. The gating strategy was 129 
performed in a similar manner to Jones et al, (2010) where the CD271+ve/CD45-/low 130 
population was gated. 131 
Flow Cytometry Acquisition and Analysis 132 
 133 
All data was obtained using a Guava easyCyte 8HT flow cytometer (Merck Millipore, UK) 134 
equipped with 488nm and 640nm excitation running guavaSoft Incyte acquisition software 135 
(v2.5). A minimum of 10,000 gated (Forward scatter/Side scatter) events were recorded for 136 
each sample. Compensation values for spectral overlap were determined using anti-mouse Ig, 137 
κ antibody capture beads as follows (CompBeads, BD Bioscience, UK). A 2ul suspension of 138 
both the positive and negative capture beads was singly stained with each fluorescent 139 
antibody as before. For the rest of the protocol CompBeads were treated in the same way as 140 
the cells. Post-acquisition analysis and compensation was performed with FlowJo v7.6.5 141 
(Treestar Inc, USA) software. 142 
Differentiation 143 
 144 
Differentiation was performed using established protocols (Chase et al. 2010). To induce 145 
osteogenic differentiation, cells were seeded into a twelve well plate at 5x103 cells/cm2 with 146 
Invitrogen StemPro Osteogenesis medium (Invitrogen, UK). The medium was changed every 147 
3-4 days. After four weeks in culture, cells were washed and fixed in 4% (v/v) 148 
paraformaldehyde (PFA) for 5 minutes at room temperature. For calcium staining, a solution 149 
of 2.5% silver nitrate (Sigma, UK) was added and cells were incubated for 30 minutes at 150 
room temperature under an ultra violet light. Counterstaining for alkaline phosphatase (ALP) 151 
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was carried out with a solution containing Fast Violet B Salt with 4% (v/v) Napthol AS-MX 152 
Phosphate Alkaline Solution (Sigma, UK) for 45 minutes at room temperature in the dark. 153 
Cells were washed three times in distilled water and visualised under a light microscope 154 
(Nikon Eclipse TS-100). 155 
 156 
To induce chondrogenic differentiation, cells were sub-cultured and re-suspended at 1.6x107 157 
cells/ml. Micromass cultures were generated by seeding a six well plate with 2 µl droplets of 158 
cell suspension and allowed to attach to the tissue flask surface in a humidified atmosphere 159 
for 30 minutes before adding pre-warmed Invitrogen StemPro Chondrogenesis medium 160 
(Invitrogen, UK). The medium was changed every 3-4 days. After 14 days in culture, cells 161 
were washed and fixed in 2% (v/v) PFA for 30 minutes at room temperature. Chondrocytes 162 
were stained with 1% (v/v) Alcian Blue in 0.1 M hydrochloric acid (HCl) solution for 30 163 
minutes, washed three times with 0.1 M HCl, diluted with distilled water and visualised 164 
under a light microscope. 165 
 166 
To induce adipogenic differentiation, cells were seeded in a twelve well plate at 1x104 167 
cells/cm2 with Invitrogen StemPro Adipogenic medium (Invitrogen, UK). The medium was 168 
changed every 3-4 days. After three weeks in culture, cells were washed and fixed in 2% 169 
(v/v) PFA for 30 minutes at room temperature. For adipogenic staining, cells were washed 170 
three times with PBS and incubated with 0.3% (v/v) Oil Red O  solution in 99% isopropanol 171 
for 30 minutes at room temperature. Cells were washed three times in distilled water and 172 
visualised under a light microscope. 173 
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 174 
Results and Discussion 175 
CD271 separation 176 
  177 
Previous work has speculated that CD271 (LNGFR) may be a specific bone marrow hMSC 178 
marker (Alvarez-Viejo et al. 2013; Jones et al. 2010). On this basis we performed MACS on 179 
two frozen BM-MNC populations using antibodies against CD271 and both resulting cell 180 
fractions were plated. After 3 weeks of culture there were no cells found within the CD271+ve 181 
sorted plates (Fig. 1a), in contrast a large adherent cell population was observed in the 182 
CD271-ve plates (Fig. 1b). The CD271-ve population expressed the CD73, CD90, CD105 183 
(≥99.9% in all cases) and did not express CD34 (5.37%) and HLA-DR (5.14%) (Fig. 1c). 184 
 185 
Previous reports have demonstrated a rare population of CD271+ve/CD45-/low cells found in 186 
bone marrow aspirates (Jones et al. 2010). Therefore we performed dual-staining flow 187 
cytometry for CD45/CD271 on the BM-MNCs. The gating strategy used to analyse the 188 
population was performed in a similar manner to previously published reports (Cox et al. 189 
2012; Jones et al. 2006). Similarly to the MACS technique we could not detect a significant 190 
number of CD271+ve cells (0.16% ± 0.02%) or the presence of a discrete population in the 191 
CD271+ve/CD45-/low gate (Fig. 1d). 192 
 193 
These findings are supported by the comprehensive proteomic profiling conducted by the US 194 
Food and Drug Administration (FDA) which only found CD271 expression in one out of four 195 
donor samples (Mindaye et al. 2013). This variability of CD271 expression has also been 196 
reported by other groups (Alvarez-Viejo et al. 2013; Siegel et al. 2013). 197 
 198 
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Single Colour Staining 199 
 200 
To validate the panel of markers for the multiparameter study the hMSC samples were first 201 
labelled with single antibodies against the markers of interest (Fig. 2). The ISCT suggests 202 
≥95% purity for expression of positive markers. Through this method, single staining results 203 
showed a highly enriched sample of the three positive markers CD73, CD90 and CD105 204 
(100%). Additionally they demonstrated little expression of the negative markers CD34 and 205 
HLA-DR (<3.5% in both cases). Due to this being outside of the ISCT range for negative 206 
markers (≤2%) we then sought to develop a multiparameter approach to find the true 207 
expression of CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/CD34-ve  in the population.  208 
 209 
Multiparameter Flow Cytometry 210 
 211 
Many publications regarding hMSC characterisation via flow cytometry employ either single 212 
or double stained populations. Although these techniques validate the expression of surface 213 
markers they do not give a representation of the population when taken together. Therefore 214 
the population was next examined using the multiparameter approach. All dual analyses of 215 
the different combinations of CD73, CD90 and CD105 showed a >99% positive population 216 
similar to the previous single colour analyses. In all cases >90% of the population fell within 217 
the HLA-DR-ve/CD34-ve gate with the overall average at 95% (Fig. 3). Taken together, these 218 
plots show that the population is a highly pure sample of hMSCs with most cells expressing 219 
the correct positive markers and lacking the selected negative markers. 220 
 221 
Serial gating was then performed to further analyse the hMSC population (Fig. 4). From the 222 
initial starting populations, defined from the forward and side scatter, each marker 223 
combination was examined in turn until a full cell surface marker phenotype was established. 224 
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The CD73+ve/CD105+ve population was first gated, and as with the dual analysis over 99% of 225 
the population expressed this combination. This quadrant was then analysed for CD90 and 226 
HLA-DR. As expected, the cell population fell within the CD90+ve/HLA-DR-ve quadrant. 227 
Finally the resulting cells were gated for CD34 and HLA-DR. As seen previously in Fig 2, 228 
the population was found in the HLA-DR-ve/CD34-ve quadrant. From this the number of cells 229 
with the surface marker expression to be CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/CD34-ve 230 
was calculated to be 94.49% ± 1.31% of the original gated population (Table 1.). This is 231 
lower when compared to results from the single staining where the population was considered 232 
to be 100% positive for a mesenchymal phenotype indicating multiparameter analysis with 233 
serial gating allows for a more stringent analysis and indicates the purity of the hMSC 234 
population. 235 
 236 
Throughout this study the cell surface markers were chosen based upon the ISCT 237 
recommendations (Dominici et al. 2006). CD73, CD90 and CD105 are all expressed on 238 
hMSCs even through extended culture, making them an ideal combination for cell 239 
identification (Bernardo et al. 2007). CD105, also known as endoglin, is a receptor for TGF-240 
β1. It is known that these receptors are mediators of cell proliferation and differentiation 241 
down the osteoblast and chondrocyte lineages whilst inhibiting the adipogenic lineage 242 
(Roelen and Dijke 2003). Upon differentiation down these lineages CD105 is down regulated 243 
making it a valuable marker of cell multipotency (Jin et al. 2009). 244 
 245 
Human MSCs are costly to isolate and culture, so by taking a multiparameter approach the 246 
phenotype analysis requires fewer cells and reagents, as well as reduced operator time 247 
representing a real cost saving for laboratories. For the multicolour assay fewer samples of 248 
cells than the usual single staining were prepared, one 5-isotype control, one unstained tube 249 
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and four multicolour test samples with an additional six wells for the compensation beads. In 250 
contrast the conventional single staining method would require at least twice this number to 251 
achieve a less stringent characterisation. This is important for autologous cell therapies, 252 
especially for older patients, where cell quantity may be limited and fewer cells are available 253 
for analysis. 254 
 255 
Differentiation 256 
 257 
To demonstrate multipotency of the hMSCs differentiation into chondrocytes, adipocytes and 258 
osteoblasts was performed using well-established techniques. To induce chondrogenic 259 
differentiation the cells were plated as micromass cultures onto tissue culture plastic with 260 
chondrogenic differentiation media. Positive Alcian Blue staining demonstrates the 261 
deposition of sulphated proteoglycans, typically secreted by chondrocytes into the 262 
extracellular matrix (Fig. 5a). After 14 days of adipogenic differentiation, treated hMSCs 263 
accumulated lipid vacuoles that are characteristic of adipocytes. The presence of lipid 264 
vacuoles was confirmed via Oil Red O staining (Fig. 5b). No lipid vacuoles were seen in the 265 
control samples. Finally, the osteogenic differentiation potential of the hMSCs was 266 
demonstrated following 21 days of culture in differentiation media.  The treated cells showed 267 
alkaline phosphatase activity as seen by Fast Violet B Salt with 4% (v/v) Napthol AS-MX 268 
Phosphate Alkaline staining (red) and calcium deposition (black) (Fig. 5c).  269 
 270 
By demonstrating the ability for trilineage differentiation into adipocytes, chondrocytes and 271 
osteoblasts as well as adherence to tissue culture plastic this fulfils the criteria outlined by the 272 
ISCT for the maintenance of hMSC phenotype. 273 
 274 
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Conclusion 275 
The aim of this study was to develop a multiparameter flow cytometry assay to analyse 276 
hMSCs at the single-cell level. Fresh bone marrow aspirates are a heterogeneous population 277 
containing several subpopulations of distinct cell types from which the hMSCs are isolated. A 278 
major obstacle for characterisation is that to date there is no single marker that defines an 279 
hMSC. As such, researchers use a panel of indicators to measure population purity creating a 280 
need for these multiparameter approaches. 281 
 282 
Multiparameter flow cytometry provides a way to determine cell phenotype based on surface 283 
proteins in a way that goes beyond the current single colour methodologies. With this method 284 
we were able to identify a population of hMSCs that express the cell surface marker panel as 285 
suggested by the ISCT. Our multiparameter assay gives a stringent analysis of the population, 286 
as each cell must pass through three separate gating strategies to be considered a fully 287 
functional hMSC. Our results show that the triple gated population was 94.49% ± 1.31% for 288 
the CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/CD34-ve expression phenotype, compared to 289 
what was considered to be 100% pure via the single staining approach. Even though this is 290 
just under the threshold value set by the ISCT we believe single stain analysis will give an 291 
overestimation of the purity of the population whereas the multiparameter method allows for 292 
full single-cell phenotype analysis thus a more stringent cell classification.  293 
 294 
Studies have suggested CD271 to be a specific marker for early passage bone-marrow 295 
hMSCs. Our findings from the flow cytometry study and MACS conducted here have 296 
indicated there is little to no expression of this marker in the cells studied here. Given the low 297 
abundance of this specific antigen and the need for a large number of cells for therapeutic use 298 
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it is concluded that CD271 may not be an appropriate marker choice on which to base the 299 
isolation of hMSCs.  300 
 301 
Whilst multiparameter flow cytometry within the stem cell community is still not widely 302 
performed recent reports suggest that this technique will become increasingly 303 
important(Zimmerlin et al. 2010; Zimmerlin et al. 2012; Khalili et al. 2012). This is attributed 304 
to a growing demand to measure multiple parameters in a single sample, thus maximising the 305 
information gathered and enhancing the depth of collected data.  306 
 307 
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 Table 1. The samples were initially gated on the single cell population followed by 379 
expression of CD105/CD73. This was then further gated on HLA-DR/CD90 and HLA-380 
DR/CD34 respectively to assess, from the starting population, the percent of cells with the 381 
CD105+ve/CD73+ve/CD90+ve/HLA-DR-ve/CD34-ve phenotype. ± values represent the SE, n ≥ 3 382 
in all cases.  383 
 384 
Figure 1. CD271 separation and analysis of bone marrow mononuclear cells. (a) Image of 385 
tissue culture flask 21 days following CD271+ve MACs separation population showing no 386 
cells. (b) CD271-ve fraction shows appearance of adherent stromal cells. Scale bar = 250µm. 387 
(c) Flow cytometry analysis of hMSCs obtained from the CD271-ve fraction shows expression 388 
of CD73, CD90 and CD105 whilst lacking CD34 and HLA-DR. (d) Dual staining for 389 
CD271/CD45 shows  an insignificant number of CD271+ve cells, 0.16% ± 0.02% (n = 3). 390 
 391 
Figure  2. Single colour flow cytometry results for expression of selected markers of hMSCs 392 
(filled). Isotype gating (outline) was set to 95%. Positive markers CD73 (PE-Cy5), CD90 393 
(APC), CD105 (PE) compared to negative markers CD34 (PE-Cy7) and HLA-DR (FITC). 394 
Graphs are representative of 4 separate experiments. 395 
 396 
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Figure 3. Five colour analysis of a single population of hMSCs. The cell surface markers 397 
CD73, CD90 and CD105 show >99% positive expression. Negative markers, CD34 and 398 
HLA-DR, were found in the negative quadrant. Isotype gating was set to 95%. Each dot plot 399 
is accompanied by bar charts that represent each quadrant showing the mean of the samples 400 
(error bars indicate the SE). n ≥ 3 in all cases. 401 
 402 
Figure 4. Serial gating of hMSCs showing co-expression of the surface markers. The initial 403 
analysis region used forward and side scatter to determine the population of interest. This was 404 
then gated for the CD73+ve and CD105+ve cells. Sequential gating was used to determine the 405 
CD90+ve/HLA-DR-ve and the HLA-DR-ve/CD34-ve population. From the initial gate 95% of 406 
cells had the CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/ CD34-ve cell surface expression 407 
phenotype. 408 
 409 
 410 
Figure  5.  Histology of differentiated mesenchymal stem cells to demonstrate multilineage 411 
potential. (a) Phase-contrast microscopy of micromass cultures differentiated down the 412 
chondrocyte lineage. The cells were fixed and stained with Alcian Blue. (b) Microscopy of 413 
cells following 14 days of adipogenic differentiation. The samples were fixed and stained 414 
with Oil Red O. (c) Phase-contrast microscopy of cells following 21 days of osteogenic 415 
differentiation. Following fixation the samples were stained using Fast Violet B Salt with 4% 416 
(v/v) Napthol AS-MX Phosphate Alkaline Solution. Magnification 10x. Scale bar = 250µm. 417 
 418 
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% Expression from Multiparameter Data  
 
Subset 1: CD105 / CD73 → Subset 2: HLA-DR / CD90 → Subset 3: HLA-DR / CD34 
% with full 
phenotype 
Exp 1 
(n=3) 
CD105- / CD73+ 0.24±0.06 
 
HLA-DR- / CD90+ 98.80±0.05 → HLA-DR- / CD34+ 7.06±2.31 
91.32±2.04% 
CD105+ / CD73+ 99.53±0.03 → HLA-DR+ / CD90+ 1.22±0.05 
 
HLA-DR+ / CD34+ 0.00±0.00 
CD105+ / CD73- 0.06±0.02 
 
HLA-DR+ / CD90- 0.00±0.00 
 
HLA-DR+ / CD34- 0.05±0.02 
CD105- / CD73- 0.16±0.02 
 
HLA-DR- / CD90- 0.00±0.00 
 
HLA-DR- / CD34- 92.87±2.28 
Exp 2 
(n=4) 
CD105- / CD73+ 0.00±0.00 
 
HLA-DR- / CD90+ 99.37±0.06 → HLA-DR- / CD34+ 1.14±0.03 
98±0.09% 
CD105+ / CD73+ 100.00±0.00 → HLA-DR+ / CD90+ 0.61±0.05 
 
HLA-DR+ / CD34+ 0.01±0.00 
CD105+ / CD73- 0.00±0.00 
 
HLA-DR+ / CD90- 0.00±0.00 
 
HLA-DR+ / CD34- 0.19±0.03 
CD105- / CD73- 0.02±0.01 
 
HLA-DR- / CD90- 0.00±0.00 
 
HLA-DR- / CD34- 98.63±0.02 
Exp 3 
(n=4) 
CD105- / CD73+ 0.01±0.00 
 
HLA-DR- / CD90+ 97.37±0.12 → HLA-DR- / CD34+ 5.46±2.20 
91.90±2.40% 
CD105+ / CD73+ 99.80±0.16 → HLA-DR+ / CD90+ 2.60±0.13 
 
HLA-DR+ / CD34+ 0.00±0.00 
CD105+ / CD73- 0.21±0.14 
 
HLA-DR+ / CD90- 0.00±0.00 
 
HLA-DR+ / CD34- 0.00±0.00 
CD105- / CD73- 0.01±0.01 
 
HLA-DR- / CD90- 0.02±0.01 
 
HLA-DR- / CD34- 94.57±2.20 
22 
 
 
 427 
 428 
Exp 4 
(n=4) 
CD105- / CD73+ 0.05±0.00 
 
HLA-DR- / CD90+ 99.10±0.05 → HLA-DR- / CD34+ 0.00±0.00 
96.72±0.68% 
CD105+ / CD73+ 99.90±0.00 → HLA-DR+ / CD90+ 0.91±0.05 
 
HLA-DR+ / CD34+ 0.00±0.00 
CD105+ / CD73- 0.02±0.00 
 
HLA-DR+ / CD90- 0.00±0.00 
 
HLA-DR+ / CD34- 2.31±0.64 
CD105- / CD73- 0.04±0.01 
 
HLA-DR- / CD90- 0.00±0.00 
 
HLA-DR- / CD34- 97.70±0.65 
